343 related articles for article (PubMed ID: 34497100)
1. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
Weber MS; Nicholas JA; Yeaman MR
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497100
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
Schneider R; Oh J
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
[TBL] [Abstract][Full Text] [Related]
4. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
McCulloch R; Eyre TA; Rule S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
[TBL] [Abstract][Full Text] [Related]
5. Bruton Tyrosine Kinase Inhibitors: Present and Future.
Burger JA
Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
[TBL] [Abstract][Full Text] [Related]
6. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Luo W; Li C; Wu J; Tang L; Wang X; Zhang Y; Wu Z; Huang Z; Xu J; Kang Y; Xiong W; Deng J; Hu Y; Mei H
Cytotherapy; 2023 Jul; 25(7):739-749. PubMed ID: 37074239
[TBL] [Abstract][Full Text] [Related]
7. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
[TBL] [Abstract][Full Text] [Related]
8. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
Torke S; Weber MS
Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
[TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
Krämer J; Wiendl H
Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Mhibik M; Wiestner A; Sun C
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.
Zhang L; Gao YH; Li SY; Zhao H; Zhang MY; Yu YY; Liu YT; Li J
Int J Hematol; 2024 Jun; 119(6):631-637. PubMed ID: 38546960
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.
Wang H; Guo H; Yang J; Liu Y; Liu X; Zhang Q; Zhou K
Exp Hematol Oncol; 2022 Sep; 11(1):60. PubMed ID: 36138486
[TBL] [Abstract][Full Text] [Related]
17. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis.
Proskuriakova E; Shrestha DB; Jasaraj R; Reddy VK; Shtembari J; Raut A; Gaire S; Khosla P; Kadariya D
Clin Ther; 2024 Feb; 46(2):134-145. PubMed ID: 38102000
[TBL] [Abstract][Full Text] [Related]
19. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
20. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
Li R; Tang H; Burns JC; Hopkins BT; Le Coz C; Zhang B; de Barcelos IP; Romberg N; Goldstein AC; Banwell BL; Luning Prak ET; Mingueneau M; Bar-Or A
Acta Neuropathol; 2022 Apr; 143(4):505-521. PubMed ID: 35303161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]